Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 12/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803940 | 0.83 | EPHX2 (0.56) | EPHX2EPHX1KDM4EALDH1A1 | |
| SCHEMBL13476616 | 0.82 | EPHX2 (0.55) | EPHX2EPHX1KDM4EALDH1A1 | |
| SCHEMBL23081209 | 0.78 | EPHX1 (0.49) | EPHX2EPHX1KDM4EALDH1A1KMT2A | |
| SCHEMBL23119053 | 0.78 | EPHX1 (0.49) | EPHX2EPHX1KDM4EALDH1A1KMT2A | |
| SCHEMBL15750233 | 0.75 | EPHX2 (0.78) | EPHX2EPHX1 | |
| SCHEMBL3665533 | 0.75 | SMYD3 (0.43) | EPHX2ALDH1A1 | |
| SCHEMBL3667582 | 0.74 | SMYD3 (0.44) | EPHX2KDM4EALDH1A1 | |
| SCHEMBL3532178 | 0.70 | EPHX2 (0.45) | EPHX2KDM4EALDH1A1KMT2A | |
| SCHEMBL23573418 | 0.69 | EPHX1 (0.42) | EPHX2EPHX1KDM4EALDH1A1 | |
| SCHEMBL12850356 | 0.69 | EPHX2 (0.58) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-7439258-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2008-10-21 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | EPHX2 2282/4885EPHX1 3653/4885KDM4E 2725/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | EPHX2 2282/4885EPHX1 3653/4885KDM4E 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.